findmyKOL
Clinical trialNCT06104618RecruitingPhase 2Interventional

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

SponsorMayo ClinicEnrollment28Metastatic Penile Squamous Cell CarcinomaStage III Penile Cancer AJCC v8Stage IV Penile Cancer AJCC v8Unresectable Penile Squamous Cell Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial tests how well enfortumab vedotin works for treating patients with squamous cell carcinoma of the penis that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona, United States

    Cassandra N. Moore, M.D.
    Recruiting
  • Mayo Clinic in Florida

    Jacksonville, Florida, United States

    Winston W. Tan, M.D.
    Recruiting
  • Mayo Clinic in Rochester

    Rochester, Minnesota, United States

    Lance C. Pagliaro, M.D.
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Enfortumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 Dec 2023
Primary completion
1 Jun 2028
Completion
1 Jun 2028
Last update posted
8 Jun 2026
Registered enrollment
28
Registry id
NCT06104618
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.